 MALVERN, Pa., Oct. 01, 2021 GLOBE NEWSWIRE -- Baudax Bio, Inc. NASDAQ:BXRX, a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that the Compensation Committee of Baudax Bios Board of Directors approved inducement grants of stock options to purchase an aggregate of 242,688 shares of Baudax Bios common stock and restricted stock units covering 79,385 shares of Baudax Bios common stock to 22 newly-hired employees, with a grant date of September 30, 2021. The equity awards were granted pursuant to the Nasdaq Rule 5635c4 inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with Baudax Bio. 